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EDITORIAL REVIEW
Clinical implications of hemodialysis membrane
biocompatibility
For more than 250,000 patients worldwide, hemodialysis is a
life-sustaining procedure; it is also associated with acute side-
effects that may be life-threatening and chronic side-effects that
diminish their quality of life. Many of these complications are
associated with the diffusive and convective components of
hemodialysis, that is, the rate of change of osmolarity and the
rate of ultrafiltration. However, in recent years, it has become
clear that hemodialysis can no longer be considered a simple
process whereby blood and dialysate are separated by an inert
semi-permeable membrane. Significant side-effects may occur
from the interactions of blood with various components of the
hemodialysis equipment [1—3].
Biocompatibility, as it relates to hemodialysis, can be defined
as the sum of specific interactions between blood and the
artificial materials of the hemodialysis circuit. Because the
components of the hemodialysis procedure are "foreign," that
is, non-self, the interaction of blood with these components is
best described as an "inflammatory response." When this
response is mild and well tolerated, the material can be termed
biocompatible. When it is intense, it may adversely affect
patient well-being or lead to deleterious outcomes. Importantly,
in the chronic hemodialysis patient these interactions are repet-
itive and occur three times a week. Therefore, even mild
interactions may, on a chronic basis, lead to adverse clinical
sequelae.
There are other aspects of the biocompatibility of the hemo-
dialysis procedure, including the biocompatibiity of the dialy-
sate (sodium concentration, acetate/bicarbonate, etc.), of the
dialytic procedure (intermittent, continuous, sequential), and of
the other components of hemodialysis (blood lines, blood
access). Finally, the initial sterilant (ethylene oxide, steam or
gamma rays), reuse procedure (manual, automated), and ster-
ilant (formaldehyde, hypochlorite, peracetic acid/hydrogen per-
oxide), as well as residual materials from the manufacturing
process (leachable phthalate), represent other aspects of bio-
compatibility of the hemodialysis procedure. However, in this
review the known interactions between blood and the new
hemodialysis membranes will be emphasized, with only limited
attention to the effect of reuse on these interactions.
Historically, cellulose-based materials were used for the
manufacturing of hemodialysis membranes and remain to date
the most commonly used membranes. Such a membrane can be
prepared by dissolution of purified cellulose (usually cotton
fibers) in an ammonia solution of cupric oxide, resulting in
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Cuprophane®. Various modifications to this repeating polysac-
charide structure of cellulosic membranes are available. These
alterations have resulted in relatively minor changes in the
characteristics of the membrane, for example, cellulose acetate
membrane, in which the polysaccharide structure is modified by
replacement of hydroxyl ions with acetate radicals. In addition,
several synthetic materials have been brought to clinical prac-
tice and, in general, are distinguished by a decrease in the
intensity and specificity of the blood membrane interactions
(Table 1).
The synthetic polymers can be grouped as either hydrophilic
or hydrophobic [4]. In general, the hydrophobic membranes are
apolar, have low energy of interactions with water, adsorb
proteins, are more porous and have high ultrafiltration coefli-
cients. This category of hydrophobic membranes includes the
polysulfone (PS), the polymethylmethacrylate (PMMA) and the
polyacrylonitrile (PAN) membranes [5]. Indeed, the ability of
these membranes to adsorb proteins may be a determinant of
their biocompatibiity, since membranes such as PAN activate
the complement system readily, but have such a high adsorptive
capacity for complement activation products that the net effect
is only a modest elevation of these products systemically [6].
Activated pathways
During contact of blood with the hemodialysis membrane,
several homeostatic reactions are activated. These include the
complement cascade, the coagulation cascade and the inter-
related contact-phase reaction. In addition to these protein-
mediated pathways, increasing evidence suggests that cellular
mechanisms can also be activated during hemodialysis, both
upon direct contact of cells with the membrane [7], as well as
byproducts of activation of the humoral pathways, such as
complement activation products. Recent work has documented
the activation of neutrophils, leading to the up-regulation of
adhesion receptors [8, 9], release of proteinases and other
intracellular enzymes, reactive oxygen species [10], leuko-
trienes [11] and platelet activating factor (PAF), as well as the
activation of monocytes leading to the production of mono-
kines, such as interleukin-1 (IL-i) and tumor necrosis factor
(TNF) [12—14], and activation of platelets leading to the release
of thromboxane B2 [15—17]. As shown in Figure 1, in many
instances these pathways are interrelated and the participation
of one leads to the participation of the other.
The details of activation of these reactions and their enzy-
matic and non-enzymatic control is beyond the scope of this
review. Instead, these reactions will be discussed in terms of
their known and potential links to clinical sequelae that have
been described in the hemodialysis patient.
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Table 1. Types of hemodialysis membranes
Membrane type Membrane structure
Cellulosic
Cellulose Polysaccharide units with hydroxyl
groups formed from cotton fibers
Derivatized cellulosic
Cellulose acetate Cellulose with 4 out of 5 hydroxyl
groups replaced with acetate
Hemophane Cellulose with 1.5% hydroxyl
groups replaced by
diethylaminoethyl radicals
Synthetic polymers
Polyetherpolycarbonate Hydrophilic synthetic
Ethylvinyl alcohol Hydrophilic synthetic
Polysulfone (PS) Hydrophobic synthetic
Polyamide Hydrophobic synthetic
Polymethylmethacrylate Hydrophobic synthetic
(PMMA)
Polyacrylonitrile (PAN) Hydrophobic synthetic
Acute sequelae of bioincompatibiity
Complement activation
Although a profound, but transient, neutropenia during he-
modialysis was initially observed in 1968, its cause remained
unknown until Craddock's elegant work documenting neutro-
penia and hypoxemia following injection of plasma that had
been exposed to cellulosic membrane into rabbits [18, 19].
Detection of products of complement activation of the common
pathway, without evidence of pronounced activation of the
classical pathway, have confirmed that complement activation
during hemodialysis occurs via the alternative pathway. The
extent of complement activation depends on the type of mem-
brane used. In general, cellulose-derived membranes result in a
much more profound activation of complement than non-
cellulosic membranes.
Much research has been devoted to the determinations of
surface structures or moieties that govern the activation of
complement by biomaterials [20, 21]. The propensity of cellu-
losic membranes to activate complement is probably related to
the polysaccharide structure of cellulose, and specifically to the
hydroxyl groups contained in this structure. More recently, the
inhibitory role of factor H of the alternative complement
pathway has been emphasized. Thus, a membrane that pro-
motes preferential binding of Factor H and does not favor the
binding of factor B has a low capacity to activate complement
[221.
The activation of complement is maximum at 15 minutes but
lasts up to at least 90 minutes, following initiation of hemodi-
alysis with new cellulose-derived membranes [23]. As hemodi-
alysis proceeds, the rate of complement activation decreases,
as suggested by the difference between the simultaneously
drawn efferent and afferent samples across the dialyzer [23].
The mechanisms of passivation of these surfaces after initiation
of hemodialysis have not been well defined, but probably
include specific deposition of complement fragments such as
C3b or Clq, as well as nonspecific deposition of fibrin on the
activating sites of the hemodialysis membrane [22].
Products of complement activation such as C3a and C5a are
potent, biologically active agents capable of producing intense
vascular smooth muscle contraction, and in several animal
models can induce anaphylaxis, hence the term "anaphylatox-
in" (Table 2). The spasmogenic effect of the anaphylatoxins on
smooth muscle cells is dose-related and the sensitivity of
different species to it is variable [24]. Animals exposed to blood
in contact with complement activating dialysis membranes
developed electrocardiographic changes consistent with isch-
emia, acute elevations of pulmonary artery pressure and acute
reduction of cardiac output, as well as increased vascular
permeability and release of histamine from mast cells [25].
Similar acute hemodynamic changes, both in the systemic and
pulmonary circulations, are also seen in animals infused with
C5a, suggesting that C5a is the putative factor in such reactions
[26].
The clinical relevance of anaphylatoxin release can be ascer-
tained from symptoms that are described in a number of
patients during their exposure to a new cellulosic dialyzer. A
number of double-blind studies have shown a marked difference
in the incidence of adverse symptoms, particularly chest pain,
back pain and shortness of breath, between new cellulosic
membranes that activate complement vigorously and repro-
cessed membranes that have a significantly attenuated ability to
activate complement [27—32]. In a prospective study, we also
showed that a subset of patients who consistently developed
chest pain, back pain and shortness of breath during the first
few minutes of bemodialysis, appeared to activate the comple-
ment pathway more vigorously (or clear the anaphylatoxin
products more slowly). In any case, these patients had levels of
C3a and C5a, which were several-fold higher than other patients
dialyzed with the same membrane surface [33]. This difference
in the level of anaphylatoxins is likely to be the explanation for
the "First-Use Syndrome" which affects 5 to 10% of patients
receiving hemodialysis with new cellulosic membranes, partic-
ularly ones with large surface areas and hence, a greater
propensity to activate complement [34]. Whether these anaphy-
latoxins act directly by themselves or via their action on mast
cells and liberation of histamine is not clear at present. It must
be stressed that these symptoms, which are directly attributable
to the extent of complement activation [35], are separate from
the reactions that have characterized some of the more dra-
matic reports of anaphylactic-type reactions and which have
been found to be due to ethylene oxide antigenicity [36—38].
Contact pathway activation
The mechanism by which a surface induces contact pathway
activation involves the binding of Hageman factor (Factor XII)
and circulating complexes of high molecular weight kininogen
(HMWK) with pre-kallikrein. Activation of Hageman factor
and pre-kallikrein results in the formation of kallikrein at the
surface and is subject to regulation by several plasma inhibitors,
such as a2-macroglobulin [39]. This pathway is more easily
activated by negatively charged surfaces, because the first step
in the activation depends on the charge-induced conformational
changes in Factor XII or Hageman factor. This conformational
change allows reciprocal activation of kallikrein and Hageman
factor. Once activated, kallikrein is also potent in liberating
kinins from HMWK as shown in Figure 1. As expected, the
extent of activation of this pathway is generally related to the
extent of negative surface charge on a membrane. A recent
study has investigated the surface charges of hemodialysis
membranes and found that whereas the Cuprophane® mem-
brane has a neutral charge, the polyacrylonitrile (PAN) mem-
brane has a high negative charge (Table 3) [39, 40]. This
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Fig. 1. Schematic diagram of multiple pathways involved in blood-membrane interactions.
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Table 2. Sequelae of complement activation (alternative pathway)
I. Release of anaphylatoxins (C3a, C5a) leading to:
Smooth muscle contraction
Increased vascular permeability
Release of histamine from mast cells
2. Formation of membrane attack complex (C5b-9)
3. Activation of neutrophils
—Degranulation and release of granulocyte enzymes (such as,
proteases)
—Production of reactive oxygen species (ROS)
—Increased expression of adhesion receptors
—Enhanced arachidonic acid metabolism (LTB4) and PAF
4. Activation of monocytes
—Increased transcription of IL-l13 and TNF-a
Membrane Charge
Cuprophane® —0
Cellulose acetate
—3.4
Polyacrylonitrile —153.9
difference in negative surface charge correlated with the degree
of Hageman factor, kallikrein activation and early bradykinin
generation.
Bradykinin is a potent vasoactive agent and is quickly de-
graded by the kininase enzymes. The clinical consequences of
contact pathway activation are generally limited in conse-
quence, except in hemodialysis membranes that have very high
negative surface charges, such as the PAN membrane, and
particularly in patients who may be on angiotensin converting
enzyme (ACE) inhibitors. ACE inhibitors not only block the
angiotensin-converting enzyme, but also the kininase enzyme
[41]. Therefore, in the presence of ACE inhibitors, bradykinin
is not degraded and a large concentration may remain in the
circulation, and severe anaphylactic reactions consisting of
cardiovascular collapse may result. Indeed, anaphylactic reac-
tions have been reported in several studies of patients dialyzed
with the AN69 polyacrylonitrile membrane who are simulta-
neously on ACE inhibitors [42, 43]. A recent report showed that
of 72 patients on a combination of ACE inhibitors and the PAN
(AN-69) membrane, 41 developed anaphylactic reactions,
whereas none of the 71 patients taking ACE inhibitors, but
dialyzed with other membranes, and only 2 of 519 patients
(0.4%) dialyzed with PAN membrane, but not on ACE inhibi-
tors, developed anaphylactic reactions [43]. Recent work by
Lemke and Fink, has shown that in the presence of ACE
inhibitors, large amounts of bradykinin are generated in a
dose-dependent manner when blood is in contact with the PAN
(AN-69) membrane, but not the Cuprophane® membrane [44].
Thus, the variability in the incidence of anaphylactic reactions
may reflect different systemic concentrations of the ACE inhib-
itors and bradykinin levels. More recently, such reactions have
been reported in patients on ACE inhibitors and dialyzed with
polysulfone and cellulose acetate membranes that have been
reused with Renalin® [45]. At present, there are no data on the
surface charges of these membranes or whether these reactions
are related to the membrane or sterilant-membrane interaction.
Chronic sequelae of bioincompatibility
Amyloid bone disease
Amyloid fibrils, consisting of f2-microglobulin (f32m) poly-
mers have been recognized as a pathologic process in long-term
hemodialysis patients since 1983. This amyloidosis, designated
A132m, is associated with a constellation of signs and symptoms,
including carpal tunnel syndrome, diffuse arthropathy, lytic
bone lesions, pathologic fractures with soft tissue swelling and
tendinitis. Ap2m is a cause of significant morbidity in the
long-term hemodialysis patient. Although amyloid bone disease
has been reported in a few patients before institution of hemo-
dialysis [46, 47], and in a few long-term peritoneal dialysis
patients [48], there is increasing evidence that the bioincompat-
ibility of hemodialysis membranes may participate in the devel-
opment of this disease process [49—511. There have been several
recent studies of large populations that have documented a
higher incidence of amyloid bone disease in patients chronically
dialyzed with cellulosic-type membranes. Although some stud-
ies showed an increase in the incidence of AJ32m in patients
dialyzed with cellulosic membrane, but which were not statis-
tically significant [521, others that were methodologically more
rigorous have shown clear-cut statistical significance [53—57].
The best example is a study by van Ypersele and his group from
Belgium, which clearly showed that the "survival without
amyloid bone disease" is significantly shorter in patients dia-
lyzed with Cuprophane® membrane than in patients dialyzed
with the PAN membrane [53]. The difference in relative risk
was clearly higher the older the patient; for example, a 60-
year-old patient dialyzed with the Cuprophane® membrane had
10 times the risk of developing Afi2m disease compared to a
similar patient on the PAN membrane [53]. It is possible that
this risk is even higher if bone biopsies are available for
diagnosis of Af32m, since other studies showed an incidence of
20% in unselected bone biopsies in patients on hemodialysis
with a Cuprophane® membrane for more than ten years [58].
The pathogenesis of the increased development of f32m amy-
bid bone disease in patients dialyzing on cellulosic membranes
is multifactorial (Table 4). 2m is expressed on the surface of all
nucleated cells; it is also released from intragranular stores by
degranulating granulocytes, as occurs during hemodialysis with
complement-activating membranes [59, 60]. In addition, several
studies have shown that the contact of mononuclear cells with
cellulosic membrane, as well as complement activation prod-
ucts CSa and C5b-9, leads to the increased transcription,
synthesis and release of /32m by these cells [61, 62]. Two in vivo
studies, in which patients were prospectively dialyzed on
biocompatible (PMMA) and bioincompatible (Cuprophane®)
membranes showed a small (20%), but statistically significant
increase in f32m production by mononuclear cells when the
patients were chronically dialyzed with the Cuprophane® mem-
brane [63, 64]. Other studies, using '31I-32m to study J32m
synthesis in different patient populations showed that patients
dialyzed with Cuprophane® membrane had a 132m synthesis rate
that was 25% higher than in patients dialyzed with a biocom-
patible membrane, although this difference was not statistically
significant, probably because of the small number of patients
studied [65]. Using similar techniques, other studies using small
numbers of different patient populations and with different
levels of residual renal function, did not show as marked a
Table 3. Surface potential of hemodialysis membranea
a Methylene blue dye method
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Table 4. Biocompatibility factors in the development of f32m amyloid
bone disease
A. Cellulosic membranes lead to an increase of synthesis and release
of f1m by MNC
B. Cellulosic membranes lead to the release of proteases (gelatinase,
elastase) and ROS which favor polymerization of /32m into
amyloid.
C. Low flux cellulosic membranes do not adsorb or clear f32m from
the circulation.
D. Biocompatible membranes favor maintenance of residual renal
function and endogenous 132m excretion.
difference [66,67]. Although serum /32m levels may not increase
appreciably during hemodialysis with cellulosic membranes,
particularly if intradialytic changes in extracellular volumes are
taken into account, it must be recalled that the additional
synthesis induced by the bioincompatibility of the membrane is
small compared to the high serum concentration of 132m that
results from loss of excretion by the native kidneys in patients
with end-stage renal disease [67—69].
An additional factor in the propensity of patients dialyzed
with cellulosic membranes to develop f32m amyloid bone dis-
ease may be due to the fact that most of the cellulosic
membranes are "low-flux" membranes; these membranes do
not have pore sizes large enough or an adsorptive surface to
effect a significant clearance of 132m from the circulation.
Because of these factors, patients dialyzed with biocompatible,
high-flux membranes, have a pre-hemodialysis plasma f32m
level that is approximately 30% lower than patients dialyzed
with the Cuprophane® membrane [70]. Thus, patients on Cu-
prophane membrane are chronically exposed to a higher level
of /.32m. More importantly however, is the fact that the activa-
tion of neutrophils by cellulosic membranes leads to the release
of proteases, as well as reactive oxygen species, which may
further enhance the polymerization of /32m into amyloid fibrils.
Indeed, analysis of the amino acid sequence of 132m amyloid
fibrils has revealed that these deposits consist of intact f3m
fibrils, as well as lysine-specific cleavage fragments of f32m that
represent limited proteolysis of /32m by proteases, such as those
released by activated neutrophils [71]. In preliminary work, we
demonstrated that f.m released by the spontaneous activation
of endothelial cells in culture can be identified as a single band
(at the 12 KD region) by gel electrophoresis, whereas f32m
released during contact with endothelial cells with CSa-activat-
ed-neutrophils had multiple bands, representing multimers of
the intact f3m molecule [72]. This suggests that a microenvi-
ronment of activated neutrophils, endothelial cells and comple-
ment fragments, such as exist in the pulmonary vasculature
during hemodialysis with cellulosic membranes, may be condu-
cive to the polymerization of f32m [73]. Thus, it is likely that the
relationship of hemodialysis with cellulosic membranes to the
development of A2m bone disease is due to a combination of
increased synthesis, lack of removal, and conditions that favor
the polymerization of p2m.
Incidence of infection
Despite many advances in the range of antimicrobial therapy
and in the care of patients on chronic maintenance hemodialysis
over the past two decades, there has been virtually no change in
the incidence of life-threatening infection in hemodialysis-
dependent patients. Many studies have shown that infections
cause approximately 20% of all deaths in this patient popula-
tion. A more recent study, using careful chart reviews, sug-
gested that infection-related mortality is much higher and
accounted for more than 36% of all deaths. Beyond six years of
hemodialysis, infections were the most common cause of death
in patients starting hemodialysis under the age of 60 years [74].
The majority of these infections are generally due to common
catalase-producing bacteria rather than to opportunistic infec-
tions.
Although patients on chronic hemodialysis have multiple
co-morbid conditions that predispose them to the development
of infections (repetitive breaks of skin integrity during cannu-
lation of fistula, malnutrition, etc.), there is increasing evidence
that the hemodialysis membrane plays an important role in this
enhanced susceptibility to infections.
The repetitive exposure of blood to bioincompatible cellulos-
ic membranes leads to the recurrent activation of complement,
degranulation of neutrophils and the release of reactive oxygen
species [10, 23]. Although the reactive oxygen species are
bactericidal, the unintended release of these molecules during
hemodialysis with cellulosic membranes results in detrimental
effects consistent with tissue injury [75], and importantly, in
decreased responsiveness to further stimuli [76]; this refracto-
riness occurs particularly intradialytically when the skin integ-
rity is violated and the patient is directly exposed to potentially
non-sterile surfaces [10, 77, 78]. Chronic hemodialysis with the
cellulosic membrane also leads to the attenuation of the ability
of neutrophils harvested pre-hemodialysis to respond to phago-
cytic stimuli [76].
Almost all studies examining granulocyte chemotaxis, adher-
ence and expression of receptors involved in phagocytosis have
demonstrated substantial defects in patients dialyzed with the
Cuprophane° membrane, even when compared to uremic pa-
tients prior to initiation of hemodialysis [76, 79, 80]. These
defects in patients dialyzed with the cellulosic membrane are
most prominent intradialytically. A recent study has also dem-
onstrated a significant decrease in the expression of L-selectins
on neutrophils harvested during hemodialysis; L-selectins are
the receptors known to be involved in granulocyte-endothelial
adhesion [81—83]. Indeed, endothelial cell adhesion has been
shown to be significantly decreased when neutrophils are
harvested during hemodialysis with the cellulosic membrane,
but not when they are harvested from patients dialyzed with the
PMMA membrane [81]. This defect may impact on the ability of
neutrophils to extravasate through endothelial cells to sites of
infection, and may thus play a role in the incidence of infections
in hemodialysis patients.
Monocytes, which function as circulating macrophages and
play a crucial role in antigen presentation and immune re-
sponse, are also activated during hemodialysis with cellulosic
membranes. Therefore, chronic exposure to these membranes
also leads to their refractoriness of monocytes to further stimuli
[10, 84, 85]. Several studies have documented defects in mono-
cyte function in hemodialysis patients, such as defective Fc-
receptor function [86] and monocyte-dependent IL-2 produc-
tion by activated T cells [87, 88]. In an in vitro model of
hemodialysis, monocyte function was found to be significantly
decreased during exposure to cellulosic membranes [85].
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Other studies have also pointed out specific defects in the
cellular immunity of patients dialyzed on different membranes
[89—92]. Recent studies from our laboratory have demonstrated
that chronic hemodialysis with cellulosic membranes exacer-
bates the defect in T cell function in hemodialysis patients. By
examining the expression of high-affinity IL-2 receptors, which
are crucial in the immune response, we found that chronic
exposure of patients to these bioincompatible membranes sig-
nificantly attenuates the expression of high affinity IL-2 recep-
tors on mononuclear cells. The change of dialyzer membrane to
a more biocompatible surface, such as PMMA, improves the
expression of these receptors and these patients have high
affinity IL-2 receptors comparable to those found in normal
controls [93]. Raij and Ray found decreased activity of natural
killer (NK) cells in blood from normal volunteers exposed to
different hemodialysis membranes [94, 95]. Our own studies
have confirmed that in patients chronically hemodialyzed with
bioincompatible membranes, there was a significant decrease in
NK cytolytic activity against their classical target cells K562
[96]. Refractoriness to mitogen stimulation, decreased prolifer-
ative response, decreased IL-2 generation and the depressed
mixed lymphocyte reactions have also been documented in
patients hemodialyzed with the Cuprophane® membrane com-
pared to patients dialyzed with biocompatible membranes [97—
99].
The association of cellulosic membranes with a higher inci-
dence of clinical infection in chronic hemodialysis patients is
supported by retrospective studies which compared the major
causes of mortality in approximately 1,000 patients before and
after their hemodialysis membranes were changed from a
cellulosic to a biocompatible membrane [100]. The most signif-
icant difference in the cause of death between these two periods
of time was in the incidence of infection, which was decreased
by approximately one-half during the period they were dialyzed
with the biocompatible polysulfone membrane. These dramatic
results were confirmed by another study, in which the rate of
hospitalization for infections in patients switched to a PS
membrane was half the rate of hospitalization for infections in
patients dialyzed with the Cuprophane® membrane [101]. In
another study, patients randomized to chronic hemodialysis
with cellulosic membranes had a significantly attenuated meta-
bolic response to phagocytic stimuli such as latex or zymosan,
compared to neutrophils similarly harvested pre-hemodialysis
from patients on the biocompatible polysulfone membrane [76].
Interestingly, during a follow-up of approximately six months,
there was also higher incidence of clinical infections in the
patients initiating hemodialysis on the Cuprophane® membrane,
compared to those initiated on the polysulfone membrane;
however, because of the small number of patients, the results
had only marginal statistical significance.
Other studies have confirmed an improvement in the lym-
phopenia in patients on chronic hemodialysis once their hemo-
dialysis membrane was changed to a biocompatible high-flux
membrane [97]. Nevertheless, studies to document changes in
clinical cellular immunity (such as, specific antibody formation
in response to vaccines) as a function of hemodialysis with
membranes of different biocompatibilities have not been pub-
lished [87, 102].
Resolution of acute renal failure
The suggestion that the dialytic procedure itself may impact
on the rate of recovery from acute renal failure (ARF) was first
put forward by Solez et al and Conger et al [103, 104]. They
examined the histology of renal tissue obtained from wounded
soldiers who developed ARF and required hemodialysis for a
prolonged period of time. They commented on the presence of
fresh areas of tubular necrosis, even though the initial injury
was remote. These observations confirmed comments by sev-
eral clinical nephrologists that the institution of hemodialysis in
patients with ARF, who may have modest residual renal
function, often causes cessation of urine flow and further loss of
residual renal function once hemodialysis is initiated. It was
postulated that loss of autoregulation of renal perfusion com-
bined with episodes of hypotension during hemodialysis results
in new areas of ischemia in the kidney [105].
Other investigators have pointed out the adverse role that
infiltrating leukocytes can play in the recovery of ARF in
several experimental models of obstruction and nephrotoxic
serum nephritis [106, 107]. More recently, Linas and his col-
leagues have shown that the adverse effects of activated neu-
trophils are particularly evident on an ischemic kidney [108].
Thus, when isolated kidneys were made mildly ischemic and
exposed to activated neutrophils, the GFR was considerably
reduced. However, this did not occur when the isolated kidneys
were exposed to non-activated neutrophils.
Our own previous work using a rat model with reversible
ARF showed that the extent of recovery of ARF in animals
exposed to stimuli that activated complement and granulocytes,
such as the cellulosic hemodialysis membrane, is considerably
less and slower than in animals with the same degree of renal
failure exposed to a biocompatible (PAN) membrane [109]. The
delayed recovery in the group of animals exposed to Cu-
prophane® was also associated with the presence of increased
numbers of activated neutrophils in the renal parenchyma.
Following this lead, a recent abstract outlined the preliminary
results of a clinical study in which patients with all forms of
ARF requiring hemodialysis were sequentially randomized to
dialyze with either Cuprophane® membrane or the biocompat-
ible low-flux PMMA membrane. These results suggest a statis-
tically significant improvement in patient mortality and in the
recovery of renal function in patients dialyzed with a biocom-
patible membrane compared to the group of patients dialyzed
with the Cuprophane® membrane. Equally important, in pa-
tients who recover, the recovery occurred earlier in the group
of patients dialyzed with the biocompatible membrane [110]. If
confirmed, the clinical implications of these findings in terms of
patient survival and hospitalization costs are quite important.
Catabolic effects of bioincompatibility
Several reports have documented the prevalence of malnu-
trition, as well as the adverse effects of this malnutrition on
morbidity and mortality of the hemodialysis patient [111].
Malnutrition often occurs with protein intakes well above the
minimum required for normal controls, suggesting a catabolic
process in the hemodialysis-dependent patients. Indeed, pa-
tients on hemodialysis appear to have an accelerated catabolic
process, which is particularly evident on hemodialysis days.
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An important and emerging factor in this catabolic process is
the hemodialysis membrane, an area that has been highlighted
by several recent studies. Those by Bergstrom, Alvestrand and
colleagues in Sweden, clearly point to a net protein catabolism
when normal subjects were exposed (not dialyzed) to cellulosic
membranes, but not when exposed to the PS or PAN (AN-69)
membrane [112, 113]. By measuring net release of specific and
total amino acids, they calculated that a 150 minute exposure to
the Cuprophane® membrane resulted in a net degradation of
approximately 15 to 20 g of muscle protein [112]. It is perhaps
worthwhile to point out that in these studies the net release of
ammo acids observed was not during the exposure to the
membrane, that is, during the first 150 minutes, but was seen
approximately six hours after the start of hemodialysis and
three hours after the end of hemodialysis. In a few subjects
where the observations were continued, the amino acid release
continued for up to nine hours after the start of hemodialysis
[112]. It is therefore important that studies of the effect of the
biocompatibility of hemodialysis membranes on the protein
catabolic rate, and the possible effects of monocyte activation
and cytokine release, be extended to the time frame in which
these cytokines are known to cause an effect. Indeed, these
observations are in line with the known time frame of monocyte
activation, release of cytokines and their subsequent action on
muscle cells [7, 14, 114].
These experimental studies are also supported by the obser-
vations of Lindsay that the relationship between the dose of
hemodialysis (Kr/V) and the protein intake (reflected by the
protein catabolic rate) was different for different membranes.
Patients dialyzed on biocompatible membranes may have a
better protein intake than patients dialyzed with a non-biocom-
patible membrane [115]. These observations are clearly in need
of further confirmation by prospective clinical studies, but the
evidence so far supports the hypothesis that the biocompatibil-
ity of the dialzyer membrane plays a substantial role in the
catabolic process associated with hemodialysis, and may be a
factor in the prevalence of malnutrition in the hemodialysis
patient [111, 113].
Morbidity and mortality of hemodialysis patients
There are, at present, no randomized studies to judge the
effects of biocompatibiity of hemodialysis membrane on the
serious morbidity (that is, hospitalization) and mortality of
hemodialysis patients. However, two non-randomized studies
support the possibility that the use of biocompatible membranes
is associated with improvement in morbidity and mortality
when compared to patients dialyzed with the cellulosic mem-
brane.
Chanard et al, studied the morbidity of hemodialysis in two
groups of patients comparable in age, the major factor deter-
mining morbidity and mortality [116]. One group of 31 patients
was dialyzed with a Cuprophane® membrane and their morbid-
ity was compared with another group of 31 patients dialyzed
with the PAN membrane over approximately 9,000 hemodialy-
sis sessions. The number of hospitalizations was significantly
higher for the Cuprophane® group (6.0 1.1 days/patient/year)
than for the PAN membrane group (2.1 0.5 days/patient/
year).
A more recent study compared the survival of patients who
were switched from hemodialysis with a Cuprophane® mem-
brane to hemodialysis with a high-flux biocompatible (PS)
membrane [101]. Of the 80 patients who died during the study
period, 69 were receiving conventional hemodialysis with cel-
lulosic membranes and 11 were receiving hemodialysis with the
high-flux, biocompatible polysulfone membrane. Multivariate
analysis, adjusted for all known comorbid conditions, showed
that annual mortality was substantially less for patients treated
with the biocompatible high-flux membrane, compared with
that for patients treated with conventional hemodialysis (7% vs.
20%, P < 0.001). Although in the study there was no difference
in the overall rate of hospital admissions, the infection-related
admissions were twice as high for the cellulosic group than for
the high-flux, bicompatible membrane group.
Finally, preliminary analysis by Lowene of more than 340
dialysis facilities in the National Medical Care system showed
that the average standardized mortality ration (SMR) for facil-
ities using high-flux polysullone membranes was 0.72 compared
to patients in dialysis units utilizing cuprophane membrane.
(P < 0.005) [117, 118].
As discussed earlier, the PS membrane differs from the
cellulosic membranes, not only in its biocompatibility but also
in terms of its high-flux capability, clearance of middle mole-
cules, and generally larger surface areas that allows for greater
reduction of urea per unit of time. The relative importance of
any of these factors in the improvement of mortality cannot be
clearly ascertained from these studies. While there are only
limited data to support the influence of middle molecules on
these outcomes [77, 119], there are data to support an influence
of urea reduction on mortality [120]. Indeed, the preliminary
analysis by Lowrie indicates that adjustment for urea reduction,
using unequilibrated post-dialysis urea levels, attenuates the
differences in average SMR. Nevertheless, units that use
polysulfone membranes still had a lower average SMR (0.83
compared to units utilizing cellulosic membranes, P = NS)
[118].
In the context of the previous disussion on the consequences
of biocompatibility on neutrophil, monocyte and lymphocyte
activation, it is likely that the biocompatibiity characteristics of
the high-flux membrane play an important role in the differences
of mortality shown by these three independent studies.
Potential sequelae of bloincompatibiity
The evidence for the sequelae of bioincompatibility of the
hemodialysis membrane in the specific areas discussed above is
supportive, but perhaps not conclusive. There are other areas in
which membrane bioincompatibility may play a role, but the
available evidence is either based primarily on animal data or in
vitro work. Nevertheless, it is worthwhile to mention those
areas as potential areas for further investigation.
Residual renal function
Clinical observations have long confirmed the possibility that
initiation of hemodialysis is associated with a rapid decrease in
the residual renal function of patients with chronic renal dis-
ease; patients who have managed to maintain a low GFR of
around 10 mllminute for several months, lose it very quickly
once they are started on bemodialysis. The rate of decline of
residual renal function is twice as fast in patients starting
hemodialysis than in patients starting peritoneal dialysis [121].
Although there are no prospective clinical trials that have
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confirmed the possible influence of bloincompatibility or the use
of cellulosic membranes on the rate of decline of residual renal
function, recent studies on animals with remnant kidneys (5/6
nephrectomies) suggest that such repetitive exposure may play
a role. In groups of animals exposed (but not dialyzed) to the
Cuprophane® membrane, there is a faster decline of residual
renal function than in identical groups exposed to the PAN
membrane [122].
The pathophysiology of these observations in patients and in
the animal model has not been elucidated. However, it is likely
that they are related to the extent of complement activation by
different hemodialysis membranes. Although the activation of
complement has been linked predominantly to the generation of
anaphylatoxins such as C3a and C5a, recent evidence suggests
that the subsequent generation of the terminal membrane attack
complex (MAC), C5b-9 may also be a clinically important
consequence of complement activation [123, 124]. A number of
studies have clearly shown that the MAC is important in the
development and propagation of several models of experimen-
tal glomerulonephritis [125]. Thus, the chronic activation of
complement resulting in the generation of C5b-9 during hemo-
dialysis with cellulosic membranes may well be involved in the
more rapid decline of residual renal function in patients initiat-
ing hemodialysis. Clinical studies to document these differences
in patients initiating hemodialysis with different membranes are
ongoing.
Pulmonary changes
The recurrent contact of activated neutrophils and pulmonary
endothelium during hemodialysis with cellulosic membranes
has been discussed as a potential mechanism that favors the
development of f32m amyloid bone disease (see above). A
specific protease that is released by activated granulocytes is
elastase [126]. Preliminary experiments in our laboratory have
confirmed that in patients dialyzed with cellulosic membranes,
there is a large increase in the concentration of elastin frag-
ments, most likely from the lung parenchyma. Although these
proteases are inactivated by several inhibitory proteins (a2-
macroglobulin), there is evidence that the inhibitory proteins
function less well in the presence of reactive oxygen species. It
is possible, therefore, that patients chronically dialyzed with
cellulosic membranes undergo chronic breakdown of their
pulmonary elastin fibrils and have a higher propensity for the
development of emphysematous changes than patients dialyzed
with biocompatible membranes [127—129]. Such a study, how-
ever, has not been done.
Dialysis associated hypoxemia is multifactorial; the major
determinant is hypoventilation seen with acetate dialysate and
changes in respiratory quotient. However, in well-designed
trails, DeBroe [29] and others [130] showed an important
contribution from membrane bioincompatibility manifested as
leukopenia.
RBC survival
Red blood cells act as major site for deposition of C5b-9, the
membrane attack complex. The presence of protein S in plasma
and two membrane proteins [homologous restriction factor
(HRF) and membrane inhibitor of reaction lysis (MIRL)] act to
attenuate the attachment of MAC on cells [131, 1321. However,
once C5b-9 is deposited, it leads to the lysis of host cells by
insertion of MAC into the membrane and by forming a lesion
that results in a lethal or sublethal damage to the cell.
The potential clinical relevance of MAC would be evident in
the determination of RBC half-life in patients dialyzed with
different membranes. This has not been examined in well-
controlled studies, but preliminary experiments in our labora-
tory suggest an increase in RBC osmotic fragility in patients
dialyzed with Cuprophane® membrane, in contrast to the same
patients dialyzed with a biocompatible membrane. Studies to
define the RBC half-life or the sensitivity to similar doses of
erythropoietin of patients dialyzed on different membranes
have not been performed so far.
Conclusions
The biocompatible hemodialysis membrane can be defined as
one that elicits the least amount of inflammatory response in
patients exposed to it. These inflammatory responses have
clinical consequences that range from acute hemodynamic
instability (as in the first use syndrome and the anaphylaxis
associated with the use of angiotensin-converting enzyme in-
hibitors and specific membranes) to the development of 132m
amyloid disease. An increased incidence of infections, slower
recovery of function after acute renal failure, and improvement
of morbidity and mortality may also be related to the biocom-
patibility characteristics of the hemodialysis membrane. Other
potential consequences include the more rapid loss of residual
renal function, development of emphysematous pulmonary
changes consistent with loss of elastin from the lung and a
decrease in RBC half-life. These actual and potential conse-
quences of the hemodialysis membrane suggest that the bio-
compatibility of the membrane should be an important consid-
eration in the prescription of hemodialysis.
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